Last reviewed · How we verify
HRS-6209 Capsules — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HRS-6209 Capsules (HRS-6209 Capsules) — Jiangsu HengRui Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HRS-6209 Capsules TARGET | HRS-6209 Capsules | Jiangsu HengRui Medicine Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HRS-6209 Capsules CI watch — RSS
- HRS-6209 Capsules CI watch — Atom
- HRS-6209 Capsules CI watch — JSON
- HRS-6209 Capsules alone — RSS
Cite this brief
Drug Landscape (2026). HRS-6209 Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/hrs-6209-capsules. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab